Melanoma antigen preferentially expressed in tumors (301-309)

Melanoma antigen preferentially expressed in tumors (301-309) is a synthetic peptide fragment derived from a tumor-associated antigen frequently identified in melanoma and other cancer types. As a nonapeptide corresponding to residues 301 to 309 of the parent protein, it is widely recognized for its immunogenic properties and relevance in tumor immunology research. This peptide is valued for its ability to mimic naturally processed epitopes presented by major histocompatibility complex (MHC) molecules, making it an essential tool for studies focused on antigen presentation, T cell recognition, and the development of immunotherapeutic strategies. Its defined sequence and biochemical stability facilitate reproducible investigations into antigen-specific cellular responses, epitope mapping, and peptide-based assay development.

Epitope mapping: Researchers utilize this peptide to precisely define T cell epitopes recognized by cytotoxic T lymphocytes (CTLs) in the context of tumor antigens. By incorporating the nonapeptide into in vitro assays, scientists can delineate the minimal sequence necessary for MHC class I binding and subsequent T cell activation. This application is instrumental in characterizing immune responses to tumor-associated antigens and in identifying immunodominant regions critical for vaccine design and immunomonitoring.

Antigen presentation studies: The peptide serves as a model substrate in investigations of antigen processing and presentation pathways. When loaded onto antigen-presenting cells or used in peptide-pulsing experiments, it enables detailed analysis of peptide-MHC complex formation, stability, and recognition by T cell receptors. These studies are fundamental for understanding how tumor antigens are naturally processed and presented, informing efforts to enhance immune detection of cancer cells.

Immunogenicity assessment: The nonapeptide is frequently employed in ex vivo and in vitro assays to assess the immunogenic potential of tumor antigens in human or murine systems. Its defined sequence allows for the quantification of antigen-specific T cell responses via techniques such as ELISPOT, intracellular cytokine staining, or tetramer staining. Such assessments are critical for evaluating candidate targets in cancer immunotherapy research and for monitoring immune responses in preclinical models.

Peptide-based assay development: The well-characterized nature of this peptide makes it a valuable standard in the development and validation of immunological assays. It can be used to calibrate and optimize assays measuring T cell activation, cytotoxicity, or cytokine production in response to tumor antigen stimulation. This application supports the establishment of robust, reproducible platforms for high-throughput screening or functional immune profiling.

Synthetic vaccine research: The peptide's role as a defined tumor antigen epitope supports its inclusion in synthetic vaccine formulations aimed at inducing targeted anti-tumor immune responses. By serving as a component in peptide-based vaccine candidates, it enables the evaluation of immunogenicity, adjuvant efficacy, and delivery strategies in preclinical settings. These studies contribute to the rational design of next-generation cancer vaccines and personalized immunotherapeutic approaches.

1. Implications of ligand-receptor binding kinetics on GLP-1R signalling

2. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

5. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)